{"filing":{"accession_number":"0001213900-26-099433","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"ea0305390-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026099433/ea0305390-6k_clearmind.htm"},"events":[{"id":33068,"run_id":30395,"accession_number":"0001213900-26-099433","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces enrollment of the first patients with Alcohol Use Disorder in Clearmind's CMND-100 clinical trial, representing a material clinical development milestone. The disclosure describes a significant operational and strategic advancement in the company's drug development program—the transition from healthy-volunteer studies to patient enrollment—which would affect a reasonable investor's assessment of the company's progress toward commercialization and value creation. While not fitting a discrete named event type, this is clearly a material operational/clinical milestone for a clinical-stage biopharmaceutical company.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36404,"accession_number":"0001213900-26-099433","item_number":"EX-99.1","item_title":"ea030539001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces enrollment of the first patients with Alcohol Use Disorder in Clearmind's CMND-100 clinical trial, representing a material clinical development milestone. The disclosure describes a significant operational and strategic advancement in the company's drug development program—the transition from healthy-volunteer studies to patient enrollment—which would affect a reasonable investor's assessment of the company's progress toward commercialization and value creation. While not fitting a discrete named event type, this is clearly a material operational/clinical milestone for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:09:38.384391+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36404,"accession_number":"0001213900-26-099433","item_number":"EX-99.1","item_title":"ea030539001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces enrollment of the first patients with Alcohol Use Disorder in Clearmind's CMND-100 clinical trial, representing a material clinical development milestone. The disclosure describes a significant operational and strategic advancement in the company's drug development program—the transition from healthy-volunteer studies to patient enrollment—which would affect a reasonable investor's assessment of the company's progress toward commercialization and value creation. While not fitting a discrete named event type, this is clearly a material operational/clinical milestone for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:09:38.384391+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-09-14"}]}